Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

Chinese Medical Journal

Volumn 119, Issue 8, 2006, Pages 649-655

  Zhang, Rui Ying ^a   Wang, Lan Feng ^a   Zhang, Lei ^a   Meng, Xiang Ning ^a   Li, Shao Jun ^a   Wang, Wu Ru ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II type I receptor blocker; Smad; Ventricular remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ACTIN; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; MESSENGER RNA; PLACEBO; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; MADH2 PROTEIN, RAT; MADH3 PROTEIN, RAT; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRESSLER SYNDROME; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART INFARCTION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DRUG COMBINATION; GENETICS; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 33646849421     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200604020-00006     Document Type: Article

References (21)

1. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
2. Chuva de Sousa Lopes SM, Feijen A, Korving J, Korchynskyi O, Larsson J, Karlsson S, et al. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn 2004; 231: 542-550.
3. Huang J, Qin GH, Hu CX, Gong LY, Chang FZ, Ma YX, et al. Effects of transforming growth factor-beta1 and signal protein Smad 3 on rat cardiomyocyte hypertrophy. Chin Med J 2004; 117: 1471-1475.
4. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IMC. Decreased Smad 7 expression contributes to cardiac fibrosis in the infracted rat heart. Am J Physiol Heart Circ Physiol 2002; 282: H1685-H1696.
5. Hao J, Wang B, Jones SC, Jassal DS, Dixon IMC. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000; 279: H3020-H3030.
6. 1-receptor blockade and angiotensin I-coverting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats. J Cardioasc Pharmacol 1999;34: 772-781.
7. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005; 117: 69-80.
8. Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kobetamehl P, Hocher B, et al. Reduction in left ventricular messenger RNA for transforming growth factor ß 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 Rat. Hypertension 2000; 36: 747-754.
9. Ammarguellat F, Larouche L, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 2001; 103: 319-324.
10. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor- βs 1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-1084.
11. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296: 1646-1647.
12. Kawano H, Do Y, Kawano Y, Starnes V, Barr M, Law RE, et al. Angiotensin II has multiple prefibrothic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-1137.
13. Schultze-Mosgau S, Blaese MA, Grabenbauer G, Wehrhan F, Kopp J, Amann K, et al. Smad-3 and Smad-7 expression following anti-transforming growth factor beta 1 (TGFbeta 1)-treatment in irradiated rat tissue. Radiother Oncol 2004; 70: 249-259.
14. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432.
15. Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999; 31: 667-678.
16. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of combination of angiotensin-coverting enzyme inhibitor and angiotensin receptor antagonist on inflammatory celluar infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1207-1215.
17. Tao ZW, Huang YW, Xia Q, Xu QW. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction. Chin Med J 2005; 118: 146-154.
18. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999; 5: 276-282.
19. Cohn JN, Tognoni G, Glazer R, Spormann D. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail 2000; 2: 439-446.
20. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takenchi K, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res 2003; 57: 48-54.
21. Velazquez EJ, Pfeffer MA, McMurray JV. VALsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003; 5: 537-544.